VERTEX PHARMACEUTICALS INCORPORATED for VERTEX PHARMACEUTICALS INCORPORATED
A later version of this report replaces this one, so LegiList's totals use the current version instead. This page shows this version exactly as filed.
Versions of this report
Every filing the register holds for this firm, client and period, oldest first. The most recent one is the version LegiList counts.
| Filing | Filed | Amount | Counted |
|---|---|---|---|
| 4th Quarter - Report (this page) | Jan 19, 2021 | $550,000 | Replaced |
| 4th Quarter - Amendment | May 21, 2021 | $570,000 | Yes |
What was lobbied
2 issue areas, each in the filer's own words, with who lobbied on it and where.
Medicare/Medicaid MMM
Issues related to rare disease and orphan disease patient access in Medicaid (no specific bills).
| Lobbyist | Covered position, as disclosed |
|---|---|
| SCOTT BARNES | — |
| MATTHEW O SCHUMAKER | — |
| SAMANTHA VENTIMIGLIA | — |
Health Issues HCR
Issues related to access to rare and orphan disease therapeutics under the enactment of ACA (no specific bills); Issues related to FDA regulatory pathways for pharmaceuticals (no specific bills); Issues related to pharmaceutical pricing (no specific bills); Issues related to health care cost and price transparency (no specific bills); Issues related to coronavirus pandemic response and extension of health programs (H.R. 133, "Consolidated Appropriations Act, 2021").
| Lobbyist | Covered position, as disclosed |
|---|---|
| SCOTT BARNES | — |
| MATTHEW O SCHUMAKER | — |
| SAMANTHA VENTIMIGLIA | — |
Shown as published by the Senate Office of Public Records and the House Clerk under the Lobbying Disclosure Act. The official filing is the record; open it for the full form.